Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 12, 2020
Daily News
March 12, 2020
- Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
- Annual Drug Price Revisions “Practically Feasible”: Health Policy Advisor
March 12, 2020
- Artz Battered by Deep Reduction as “G2” Price Cut Applied for Second Time
March 12, 2020
- Ninlaro Misses Primary Goal in Front-Line Myeloma Study
March 12, 2020
- Nipro Confirms Coronavirus Infection Case at Niigata Branch
March 12, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Santen Calls Off Development of wAMD Treatment after PIIa Fails
March 12, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Singapore
March 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…